Ovid Therapeutics News

The Latest Analyst Ratings For Ovid Therapeutics

BenzingaJul 26 14:03 ET

Ovid Therapeutics Analyst Ratings

BenzingaJul 26 07:29 ET

Buy Rating Affirmed for Ovid Therapeutics on Advisory Expansion and Promising Epilepsy Drug Prospects

TipRanksJul 26 06:47 ET

Analysts Have Conflicting Sentiments on These Healthcare Companies: Ovid Therapeutics (OVID) and Dexcom (DXCM)

TipRanksJul 26 06:39 ET

H.C. Wainwright Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Maintains Target Price $3

Moomoo NewsJul 26 06:31 ET

Ovid Therapeutics Analyst Ratings

BenzingaJul 2 06:25 ET

HC Wainwright & Co. Reiterates Buy on Ovid Therapeutics, Maintains $3 Price Target

BenzingaJul 2 06:24 ET

Buy Rating Affirmed for Ovid Therapeutics Following Promising Phase 1 Results of OV888/GV101

TipRanksJul 2 06:20 ET

Ovid Therapeutics' Promising Drug Safety and Biomarker Developments Garner Buy Rating

TipRanksJul 1 21:17 ET

Buy Rating for Ovid Therapeutics Backed by Strong Clinical Data and Strategic Management

TipRanksJul 1 12:59 ET

Oppenheimer Cuts Ovid to Perform, Cites Uncertainty Over Lead Drug

Seeking AlphaJun 18 12:29 ET

Ovid Therapeutics Analyst Ratings

BenzingaJun 18 08:20 ET

B. Riley Adjusts Price Target on Ovid Therapeutics to $3 From $9, Maintains Buy Rating

MT NewswiresJun 18 06:25 ET

Buy Rating for Ovid Therapeutics Based on Novel SE Drug Candidates OV329 and OV350

TipRanksMay 20 06:00 ET

Ovid Therapeutics Analyst Ratings

BenzingaMay 16 07:08 ET

Buy Rating for Ovid Therapeutics Based on Promising Drug Trials and Strategic Partnerships

TipRanksMay 16 06:40 ET

TD Cowen Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)

TipRanksMay 15 07:20 ET

Ovid Therapeutics Analyst Ratings

BenzingaMay 7 13:42 ET

Citigroup Maintains Neutral on Ovid Therapeutics, Lowers Price Target to $3.5

BenzingaMay 7 13:42 ET

Ovid Therapeutics Analyst Ratings

BenzingaApr 30 08:37 ET